Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Abstract Text:

Excessive cell proliferation contributes to the pathobiology of human diseases with a high health and socio-economic impact, including cancer and vascular occlusive diseases (e. g., atherosclerosis, in-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Recent advances in the understanding of the molecular networks governing the hyperplastic growth of tumors and vascular obstructive neointimal lesions have provided new perspectives for preventive and therapeutic strategies against these disorders. Mammalian cell proliferation requires the activation of several cyclin-dependent protein kinases (CDKs). Postranslational activation of CDKs is a complex process that involves their association with regulatory subunits called cyclins. The activity of CDK/cyclin holoenzymes is negatively regulated through their interaction with members of the CDK family of inhibitory proteins (CKIs). Moreover, over fifty low molecular weight pharmacological CDK inhibitors that target the ATP-binding pocket of the catalytic site of CDKs have been identified. In this review, we will discuss the use of pharmacological and gene therapy strategies against CDK/cyclins in animal models and clinical trials of cancer and cardiovascular disease.

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Publishing Authors By Initials

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Current pharmaceutical biotechnology

VOLUME: 4

Page Numbers: 21-37

Journal Abbreviation: Curr Pharm Biotechnol

ISSN: 1389-2010

DAY: 12

MONTH: Feb

YEAR: 2003

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Information

Number of References: 234

LANGUAGE: eng

NlmUniqueID: 100960530

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: enzymology

Chemical & Substance for Abstract: Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Information

Substance Name: Cyclin-Dependent Kinases

Registry Number: EC 2.7.1.37

Grant and Affiliation Information for Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.

AFFILIATION: Laboratory of Vascular Biology, Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia, Spanish Council for Scientific Research, Valencia, Spain.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Pharm Biotechnol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease Related Publications

• A Theoretical Study on the Electronic Structure of Au-XO((0,-1,+1)) (X = C, N, and O) Complexes: Effect of an External Electric Field.
• A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation.
• Aggressive form of multiple myeloma presenting with specific pleural effusion, neutrophilia, and eosinophilia.
• Ambiguity function analysis of pulse train propagation: applications to temporal Lau filtering.
• Broadband space-variant Fresnel processor.
• Faut-il circoncire les nouveau-nes?: NON.
• Focal-shift formula in apodized nontelecentric focusing systems.
• Full-vector analysis of a realistic photonic crystal fiber.
• Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593.
• Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis.
• Nearly zero ultraflattened dispersion in photonic crystal fibers.
• Optical security and encryption with totally incoherent light.
• Parvovirus B19 infection as a cause of cytopenia with a lupus-like presentation in the elderly: A case report.
• Plasma membrane targeting is essential for Rem-mediated Ca2+ channel inhibition.
• Prevention of clinical mastitis with barium selenate in dairy goats from a selenium-deficient area.
• Proliferation and apoptosis in mammary epithelium during the rat oestrous cycle.
• Rebuttal: Should newborns be circumcised?: NO.
• Rit mutants confirm role of MEK/ERK signaling in neuronal differentiation and reveal novel Par6 interaction.
• Sexual dimorphism and the genetic potential for evolution of sex allocation in the gynodioecious plant, Schiedea salicaria.
• Should newborns be circumcised?: NO.
• Spectral imaging system for scaling the power spectrum of optical waveforms.
• Telomere dysfunction in hypertension.
• The RGK family of GTP-binding proteins: Regulators of voltage-dependent calcium channels and cytoskeleton remodeling.
• The novel GTPase Rit differentially regulates axonal and dendritic growth.
• Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue.
• Transmission disequilibrium study of an oligodendrocyte and myelin glycoprotein gene allele in 431 families with an autistic proband.
• Universal alternating order around impurities in antiferromagnets.
• Wavelength-compensated Fourier and Fresnel transformers: a unified approach.
• [Not Available.]
• [Recurrent acute fatty liver of pregnancy.]